Diligence memo · auto-generated · as of July 2, 2026
Pluto Immunotherapeutics, Inc.
Pluto Immunotherapeutics, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Pluto Immunotherapeutics, Inc. operates in Biotechnology, based in LOS ANGELES.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Pluto Immunotherapeutics, Inc. has raised $5.0M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $2.8M on 2021-12-22.
Most recent recorded round closed around 2021-12-22.
Valuation (modeled)modeled
Provath models Pluto Immunotherapeutics, Inc. at approximately $54M (range $2.0M–$286M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.84× the median modeled value of Seed Biotechnology companies in 2019–2021 (186 peers) — value vs value, same stage and era. Within the normal band (84% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 14 months.
Last raise 4.5 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 1.3× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 43% of Biotechnology peers (4293 compared).
Modeled value ranks above 47% of those peers.
Closest niche peers: Novo Biosciences, Inc., Entac Medical, Inc., ReGelTec, Inc., Korro Bio, Inc., TamuroBio Inc..
Peoplefiled
5 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.